E.U. committee recommends authorization of BioNTech and Pfizer’s coronavirus vaccine

/ / News

Shares of Pfizer Inc. were down 1.1% and BioNTech SE shares were up 1.2% in trading on Monday after the companies said their COVID-19 vaccine has been recommended for authorization in the European Union. The Committee for Medicinal Products for Human Use made the recommendation, and the European Commission is expected to review it and make a final decision in the “near future.” If authorized, this would be the first COVID-19 vaccine available in Europe. “Today is a particularly personal and emotional day for us at BioNTech,” BioNTech CEO Ugar Sahin said in a statement. “Being in the heart of the E.U., we are thrilled to be one step closer to potentially delivering the first vaccine in Europe to help combat this devastating pandemic.” BioNTech and Pfizer’s vaccine received emergency use authorization in the U.S. earlier this month. So far this year, shares of BioNTech have soared 212.2%, Pfizer’s stock is up 0.2%, and the S&P 500 has gained 14.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.